Asymmetrical flow field-flow fractionation for human serum albumin based nanoparticle characterisation and a deeper insight into particle formation processes.

Nanoparticles used as drug delivery systems are of growing interest in the pharmaceutical field. Understanding the behaviour and effects of nanosystems in the human body is dependent on comprehensive characterisation of the systems especially with regard to size and size distribution. Asymmetrical flow field-flow fractionation (AF4) is a promising method for this challenge as this technique enables chromatographic separation of particles and solute molecules according to their respective size. Within this study AF4 was used for the characterisation of human serum albumin (HSA) based nanoparticles. In a first part, the most important aspects of method development like the choice of cross flow rate, focusing and the increase of sample concentration via outlet stream splitting on the sample separation were evaluated. Sample fractionation was controlled by inline-coupling of a dynamic light scattering detector (DLS, Zetasizer) and was confirmed by DLS batch mode measurements. In a second part the applicability of field-flow fractionation for characterisation of the HSA particle formation process by a desolvation method was evaluated. A time dependent particle formation was observed which was controlled by the amount of desolvating agent. Furthermore, field-flow fractionation in combination with in-line dynamic light scattering was used to monitor the increase of particle diameter during PEGylation of the resulting HSA nanoparticles. The separation of nanoparticles from dissolved polyethylene glycol (PEG) could successfully be used for determination of the particles' PEGylation degree.